nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—VEGFA—brain cancer	0.225	0.565	CbGaD
Carvedilol—XDH—Procarbazine—brain cancer	0.203	0.558	CbGbCtD
Carvedilol—CYP2C9—brain cancer	0.173	0.435	CbGaD
Carvedilol—XDH—Carboplatin—brain cancer	0.0497	0.137	CbGbCtD
Carvedilol—CYP2D6—Lomustine—brain cancer	0.0185	0.0509	CbGbCtD
Carvedilol—CYP1A2—Carmustine—brain cancer	0.0183	0.0504	CbGbCtD
Carvedilol—CYP2D6—Hydroxyurea—brain cancer	0.014	0.0386	CbGbCtD
Carvedilol—CYP3A4—Temozolomide—brain cancer	0.0139	0.0381	CbGbCtD
Carvedilol—PTGS1—Etoposide—brain cancer	0.0122	0.0334	CbGbCtD
Carvedilol—CYP3A4—Lomustine—brain cancer	0.0118	0.0324	CbGbCtD
Carvedilol—CYP2E1—Etoposide—brain cancer	0.0094	0.0258	CbGbCtD
Carvedilol—CYP1A2—Etoposide—brain cancer	0.00543	0.0149	CbGbCtD
Carvedilol—SELE—vein—brain cancer	0.00505	0.0717	CbGeAlD
Carvedilol—ABCB1—Etoposide—brain cancer	0.00475	0.0131	CbGbCtD
Carvedilol—VCAM1—vein—brain cancer	0.00464	0.0659	CbGeAlD
Carvedilol—CYP3A4—Etoposide—brain cancer	0.00285	0.00783	CbGbCtD
Carvedilol—NPPB—blood vessel—brain cancer	0.00237	0.0337	CbGeAlD
Carvedilol—SELE—endothelium—brain cancer	0.00174	0.0247	CbGeAlD
Carvedilol—GJA1—ganglion—brain cancer	0.00173	0.0246	CbGeAlD
Carvedilol—SELE—blood vessel—brain cancer	0.0016	0.0227	CbGeAlD
Carvedilol—VCAM1—endothelium—brain cancer	0.0016	0.0227	CbGeAlD
Carvedilol—HIF1A—endothelium—brain cancer	0.00154	0.0218	CbGeAlD
Carvedilol—GJA1—endothelium—brain cancer	0.00149	0.0212	CbGeAlD
Carvedilol—VCAM1—blood vessel—brain cancer	0.00147	0.0209	CbGeAlD
Carvedilol—HIF1A—blood vessel—brain cancer	0.00142	0.0201	CbGeAlD
Carvedilol—GJA1—blood vessel—brain cancer	0.00137	0.0195	CbGeAlD
Carvedilol—HIF1A—hindbrain—brain cancer	0.00135	0.0192	CbGeAlD
Carvedilol—GJA1—hindbrain—brain cancer	0.00131	0.0186	CbGeAlD
Carvedilol—HIF1A—brainstem—brain cancer	0.000775	0.011	CbGeAlD
Carvedilol—GJA1—brainstem—brain cancer	0.000751	0.0107	CbGeAlD
Carvedilol—NPPB—endocrine gland—brain cancer	0.000725	0.0103	CbGeAlD
Carvedilol—NPPB—head—brain cancer	0.000716	0.0102	CbGeAlD
Carvedilol—HIF1A—telencephalon—brain cancer	0.000687	0.00976	CbGeAlD
Carvedilol—GJA1—telencephalon—brain cancer	0.000667	0.00947	CbGeAlD
Carvedilol—NPPB—central nervous system—brain cancer	0.000654	0.00928	CbGeAlD
Carvedilol—SELE—pituitary gland—brain cancer	0.000632	0.00898	CbGeAlD
Carvedilol—SELE—medulla oblongata—brain cancer	0.00061	0.00867	CbGeAlD
Carvedilol—VCAM1—pituitary gland—brain cancer	0.000582	0.00826	CbGeAlD
Carvedilol—NDUFC2—telencephalon—brain cancer	0.00058	0.00824	CbGeAlD
Carvedilol—HIF1A—gonad—brain cancer	0.000574	0.00815	CbGeAlD
Carvedilol—VCAM1—medulla oblongata—brain cancer	0.000561	0.00797	CbGeAlD
Carvedilol—HIF1A—pituitary gland—brain cancer	0.00056	0.00795	CbGeAlD
Carvedilol—SELE—midbrain—brain cancer	0.000558	0.00792	CbGeAlD
Carvedilol—GJA1—gonad—brain cancer	0.000557	0.0079	CbGeAlD
Carvedilol—SELE—spinal cord—brain cancer	0.000544	0.00773	CbGeAlD
Carvedilol—GJA1—pituitary gland—brain cancer	0.000543	0.00771	CbGeAlD
Carvedilol—HIF1A—medulla oblongata—brain cancer	0.00054	0.00767	CbGeAlD
Carvedilol—VEGFA—telencephalon—brain cancer	0.000527	0.00748	CbGeAlD
Carvedilol—GJA1—medulla oblongata—brain cancer	0.000524	0.00744	CbGeAlD
Carvedilol—NPPB—brain—brain cancer	0.000519	0.00737	CbGeAlD
Carvedilol—VCAM1—midbrain—brain cancer	0.000513	0.00729	CbGeAlD
Carvedilol—VCAM1—spinal cord—brain cancer	0.000501	0.00711	CbGeAlD
Carvedilol—HIF1A—midbrain—brain cancer	0.000494	0.00701	CbGeAlD
Carvedilol—SELE—endocrine gland—brain cancer	0.00049	0.00696	CbGeAlD
Carvedilol—NDUFC2—gonad—brain cancer	0.000484	0.00688	CbGeAlD
Carvedilol—SELE—head—brain cancer	0.000484	0.00687	CbGeAlD
Carvedilol—HIF1A—spinal cord—brain cancer	0.000482	0.00684	CbGeAlD
Carvedilol—GJA1—midbrain—brain cancer	0.000479	0.0068	CbGeAlD
Carvedilol—NDUFC2—pituitary gland—brain cancer	0.000473	0.00671	CbGeAlD
Carvedilol—GJA1—spinal cord—brain cancer	0.000467	0.00664	CbGeAlD
Carvedilol—NDUFC2—medulla oblongata—brain cancer	0.000456	0.00648	CbGeAlD
Carvedilol—VCAM1—endocrine gland—brain cancer	0.000451	0.0064	CbGeAlD
Carvedilol—VCAM1—head—brain cancer	0.000445	0.00632	CbGeAlD
Carvedilol—SELE—central nervous system—brain cancer	0.000442	0.00627	CbGeAlD
Carvedilol—HIF1A—endocrine gland—brain cancer	0.000434	0.00616	CbGeAlD
Carvedilol—SELE—cerebellum—brain cancer	0.000432	0.00613	CbGeAlD
Carvedilol—VEGFA—pituitary gland—brain cancer	0.000429	0.00609	CbGeAlD
Carvedilol—HIF1A—head—brain cancer	0.000428	0.00608	CbGeAlD
Carvedilol—GJA1—endocrine gland—brain cancer	0.000421	0.00597	CbGeAlD
Carvedilol—NDUFC2—midbrain—brain cancer	0.000417	0.00592	CbGeAlD
Carvedilol—GJA1—head—brain cancer	0.000415	0.0059	CbGeAlD
Carvedilol—NDUFC2—spinal cord—brain cancer	0.000407	0.00578	CbGeAlD
Carvedilol—VCAM1—central nervous system—brain cancer	0.000406	0.00577	CbGeAlD
Carvedilol—HIF1A—central nervous system—brain cancer	0.000391	0.00555	CbGeAlD
Carvedilol—ADRA1A—hindbrain—brain cancer	0.000388	0.00552	CbGeAlD
Carvedilol—HIF1A—cerebellum—brain cancer	0.000382	0.00542	CbGeAlD
Carvedilol—GJA1—central nervous system—brain cancer	0.000379	0.00538	CbGeAlD
Carvedilol—GJA1—cerebellum—brain cancer	0.00037	0.00526	CbGeAlD
Carvedilol—VEGFA—spinal cord—brain cancer	0.000369	0.00524	CbGeAlD
Carvedilol—PTGS1—ganglion—brain cancer	0.000367	0.00521	CbGeAlD
Carvedilol—NDUFC2—endocrine gland—brain cancer	0.000366	0.0052	CbGeAlD
Carvedilol—NDUFC2—head—brain cancer	0.000361	0.00513	CbGeAlD
Carvedilol—SELE—brain—brain cancer	0.000351	0.00498	CbGeAlD
Carvedilol—ADRA1D—telencephalon—brain cancer	0.000344	0.00489	CbGeAlD
Carvedilol—NDUFC2—central nervous system—brain cancer	0.00033	0.00469	CbGeAlD
Carvedilol—NDUFC2—cerebellum—brain cancer	0.000322	0.00458	CbGeAlD
Carvedilol—VCAM1—brain—brain cancer	0.000322	0.00458	CbGeAlD
Carvedilol—PTGS1—endothelium—brain cancer	0.000316	0.00449	CbGeAlD
Carvedilol—HIF1A—brain—brain cancer	0.00031	0.00441	CbGeAlD
Carvedilol—GJA1—brain—brain cancer	0.000301	0.00427	CbGeAlD
Carvedilol—XDH—endocrine gland—brain cancer	0.000296	0.0042	CbGeAlD
Carvedilol—VEGFA—cerebellum—brain cancer	0.000293	0.00415	CbGeAlD
Carvedilol—PTGS1—blood vessel—brain cancer	0.000292	0.00415	CbGeAlD
Carvedilol—NDUFC2—brain—brain cancer	0.000262	0.00372	CbGeAlD
Carvedilol—ADRB1—telencephalon—brain cancer	0.00025	0.00355	CbGeAlD
Carvedilol—VEGFA—brain—brain cancer	0.000238	0.00337	CbGeAlD
Carvedilol—CYP2D6—hindbrain—brain cancer	0.000229	0.00325	CbGeAlD
Carvedilol—ADRA1A—brainstem—brain cancer	0.000223	0.00316	CbGeAlD
Carvedilol—ADRA1B—head—brain cancer	0.000219	0.00311	CbGeAlD
Carvedilol—ADRA1D—endocrine gland—brain cancer	0.000217	0.00308	CbGeAlD
Carvedilol—ADRA1D—head—brain cancer	0.000214	0.00304	CbGeAlD
Carvedilol—ADRA1B—central nervous system—brain cancer	0.0002	0.00284	CbGeAlD
Carvedilol—ADRA1A—telencephalon—brain cancer	0.000198	0.00281	CbGeAlD
Carvedilol—ADRA1D—central nervous system—brain cancer	0.000196	0.00278	CbGeAlD
Carvedilol—Erectile dysfunction—Temozolomide—brain cancer	0.000191	0.00244	CcSEcCtD
Carvedilol—Thrombocytopenia—Procarbazine—brain cancer	0.000191	0.00244	CcSEcCtD
Carvedilol—Depression—Carmustine—brain cancer	0.000191	0.00243	CcSEcCtD
Carvedilol—KCNH2—telencephalon—brain cancer	0.000191	0.00271	CbGeAlD
Carvedilol—Tachycardia—Procarbazine—brain cancer	0.00019	0.00243	CcSEcCtD
Carvedilol—Photosensitivity reaction—Temozolomide—brain cancer	0.000189	0.00242	CcSEcCtD
Carvedilol—Weight increased—Temozolomide—brain cancer	0.000189	0.00241	CcSEcCtD
Carvedilol—Hyperhidrosis—Procarbazine—brain cancer	0.000189	0.00241	CcSEcCtD
Carvedilol—ADRA2C—telencephalon—brain cancer	0.000188	0.00267	CbGeAlD
Carvedilol—Renal failure—Carmustine—brain cancer	0.000188	0.0024	CcSEcCtD
Carvedilol—Alopecia—Hydroxyurea—brain cancer	0.000188	0.0024	CcSEcCtD
Carvedilol—Weight decreased—Temozolomide—brain cancer	0.000188	0.00239	CcSEcCtD
Carvedilol—Hyperglycaemia—Temozolomide—brain cancer	0.000187	0.00239	CcSEcCtD
Carvedilol—Urinary tract infection—Carmustine—brain cancer	0.000186	0.00237	CcSEcCtD
Carvedilol—Pneumonia—Temozolomide—brain cancer	0.000186	0.00237	CcSEcCtD
Carvedilol—Anorexia—Procarbazine—brain cancer	0.000186	0.00237	CcSEcCtD
Carvedilol—Depression—Temozolomide—brain cancer	0.000184	0.00235	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000183	0.00234	CcSEcCtD
Carvedilol—Cardiac arrest—Etoposide—brain cancer	0.000183	0.00233	CcSEcCtD
Carvedilol—Nausea—Lomustine—brain cancer	0.000183	0.00233	CcSEcCtD
Carvedilol—Hypotension—Procarbazine—brain cancer	0.000182	0.00233	CcSEcCtD
Carvedilol—Urinary tract infection—Temozolomide—brain cancer	0.00018	0.00229	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000178	0.00227	CcSEcCtD
Carvedilol—Insomnia—Procarbazine—brain cancer	0.000176	0.00225	CcSEcCtD
Carvedilol—Paraesthesia—Procarbazine—brain cancer	0.000175	0.00224	CcSEcCtD
Carvedilol—Sinusitis—Temozolomide—brain cancer	0.000174	0.00221	CcSEcCtD
Carvedilol—Somnolence—Procarbazine—brain cancer	0.000173	0.00221	CcSEcCtD
Carvedilol—Cramp muscle—Etoposide—brain cancer	0.000173	0.00221	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000173	0.00221	CcSEcCtD
Carvedilol—Haemoglobin—Carmustine—brain cancer	0.000173	0.0022	CcSEcCtD
Carvedilol—ABCB1—blood vessel—brain cancer	0.000173	0.00245	CbGeAlD
Carvedilol—Haemorrhage—Carmustine—brain cancer	0.000172	0.00219	CcSEcCtD
Carvedilol—Ill-defined disorder—Hydroxyurea—brain cancer	0.000172	0.00219	CcSEcCtD
Carvedilol—Anaemia—Hydroxyurea—brain cancer	0.000171	0.00218	CcSEcCtD
Carvedilol—Hypoaesthesia—Carmustine—brain cancer	0.000171	0.00218	CcSEcCtD
Carvedilol—Decreased appetite—Procarbazine—brain cancer	0.00017	0.00216	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Etoposide—brain cancer	0.000169	0.00216	CcSEcCtD
Carvedilol—Oedema peripheral—Carmustine—brain cancer	0.000169	0.00216	CcSEcCtD
Carvedilol—Fatigue—Procarbazine—brain cancer	0.000168	0.00215	CcSEcCtD
Carvedilol—Haemoglobin—Temozolomide—brain cancer	0.000167	0.00213	CcSEcCtD
Carvedilol—Malaise—Hydroxyurea—brain cancer	0.000167	0.00213	CcSEcCtD
Carvedilol—Constipation—Procarbazine—brain cancer	0.000167	0.00213	CcSEcCtD
Carvedilol—Pain—Procarbazine—brain cancer	0.000167	0.00213	CcSEcCtD
Carvedilol—Haemorrhage—Temozolomide—brain cancer	0.000166	0.00212	CcSEcCtD
Carvedilol—Leukopenia—Hydroxyurea—brain cancer	0.000166	0.00211	CcSEcCtD
Carvedilol—Visual impairment—Carmustine—brain cancer	0.000166	0.00211	CcSEcCtD
Carvedilol—Hypoaesthesia—Temozolomide—brain cancer	0.000165	0.00211	CcSEcCtD
Carvedilol—Pharyngitis—Temozolomide—brain cancer	0.000165	0.0021	CcSEcCtD
Carvedilol—Urinary tract disorder—Temozolomide—brain cancer	0.000164	0.00209	CcSEcCtD
Carvedilol—Oedema peripheral—Temozolomide—brain cancer	0.000164	0.00209	CcSEcCtD
Carvedilol—Bronchospasm—Etoposide—brain cancer	0.000163	0.00208	CcSEcCtD
Carvedilol—Urethral disorder—Temozolomide—brain cancer	0.000163	0.00208	CcSEcCtD
Carvedilol—Sweating increased—Etoposide—brain cancer	0.000162	0.00206	CcSEcCtD
Carvedilol—Feeling abnormal—Procarbazine—brain cancer	0.000161	0.00205	CcSEcCtD
Carvedilol—Convulsion—Hydroxyurea—brain cancer	0.00016	0.00205	CcSEcCtD
Carvedilol—Visual impairment—Temozolomide—brain cancer	0.00016	0.00204	CcSEcCtD
Carvedilol—Gastrointestinal pain—Procarbazine—brain cancer	0.00016	0.00204	CcSEcCtD
Carvedilol—ADRA1B—brain—brain cancer	0.000159	0.00225	CbGeAlD
Carvedilol—Pancytopenia—Etoposide—brain cancer	0.000158	0.00201	CcSEcCtD
Carvedilol—ADRB1—endocrine gland—brain cancer	0.000158	0.00224	CbGeAlD
Carvedilol—Erythema multiforme—Temozolomide—brain cancer	0.000157	0.002	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000156	0.002	CcSEcCtD
Carvedilol—Discomfort—Hydroxyurea—brain cancer	0.000156	0.00199	CcSEcCtD
Carvedilol—ADRB1—head—brain cancer	0.000156	0.00221	CbGeAlD
Carvedilol—KCNH2—pituitary gland—brain cancer	0.000155	0.00221	CbGeAlD
Carvedilol—ADRA1D—brain—brain cancer	0.000155	0.0022	CbGeAlD
Carvedilol—Urticaria—Procarbazine—brain cancer	0.000155	0.00198	CcSEcCtD
Carvedilol—Tinnitus—Temozolomide—brain cancer	0.000155	0.00198	CcSEcCtD
Carvedilol—Abdominal pain—Procarbazine—brain cancer	0.000154	0.00197	CcSEcCtD
Carvedilol—Body temperature increased—Procarbazine—brain cancer	0.000154	0.00197	CcSEcCtD
Carvedilol—ADRA2C—pituitary gland—brain cancer	0.000153	0.00218	CbGeAlD
Carvedilol—Alopecia—Carmustine—brain cancer	0.000152	0.00194	CcSEcCtD
Carvedilol—Oedema—Hydroxyurea—brain cancer	0.000151	0.00193	CcSEcCtD
Carvedilol—Angiopathy—Temozolomide—brain cancer	0.000151	0.00192	CcSEcCtD
Carvedilol—ADRA2A—telencephalon—brain cancer	0.00015	0.00213	CbGeAlD
Carvedilol—Infection—Hydroxyurea—brain cancer	0.00015	0.00191	CcSEcCtD
Carvedilol—Immune system disorder—Temozolomide—brain cancer	0.00015	0.00191	CcSEcCtD
Carvedilol—KCNH2—medulla oblongata—brain cancer	0.00015	0.00213	CbGeAlD
Carvedilol—Mediastinal disorder—Temozolomide—brain cancer	0.00015	0.00191	CcSEcCtD
Carvedilol—Malnutrition—Carmustine—brain cancer	0.00015	0.00191	CcSEcCtD
Carvedilol—Pneumonia—Etoposide—brain cancer	0.000149	0.0019	CcSEcCtD
Carvedilol—ADRA2C—medulla oblongata—brain cancer	0.000148	0.0021	CbGeAlD
Carvedilol—Thrombocytopenia—Hydroxyurea—brain cancer	0.000148	0.00189	CcSEcCtD
Carvedilol—CYP2E1—telencephalon—brain cancer	0.000147	0.00209	CbGeAlD
Carvedilol—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000147	0.00187	CcSEcCtD
Carvedilol—Alopecia—Temozolomide—brain cancer	0.000147	0.00187	CcSEcCtD
Carvedilol—Skin disorder—Hydroxyurea—brain cancer	0.000147	0.00187	CcSEcCtD
Carvedilol—Acute coronary syndrome—Etoposide—brain cancer	0.000146	0.00186	CcSEcCtD
Carvedilol—Renal failure—Etoposide—brain cancer	0.000145	0.00186	CcSEcCtD
Carvedilol—Myocardial infarction—Etoposide—brain cancer	0.000145	0.00185	CcSEcCtD
Carvedilol—Back pain—Carmustine—brain cancer	0.000145	0.00185	CcSEcCtD
Carvedilol—Malnutrition—Temozolomide—brain cancer	0.000145	0.00184	CcSEcCtD
Carvedilol—Anorexia—Hydroxyurea—brain cancer	0.000144	0.00184	CcSEcCtD
Carvedilol—Hypersensitivity—Procarbazine—brain cancer	0.000144	0.00183	CcSEcCtD
Carvedilol—ADRB1—central nervous system—brain cancer	0.000142	0.00202	CbGeAlD
Carvedilol—PTGS1—telencephalon—brain cancer	0.000142	0.00201	CbGeAlD
Carvedilol—Vision blurred—Carmustine—brain cancer	0.000141	0.0018	CcSEcCtD
Carvedilol—Asthenia—Procarbazine—brain cancer	0.00014	0.00179	CcSEcCtD
Carvedilol—Back pain—Temozolomide—brain cancer	0.00014	0.00178	CcSEcCtD
Carvedilol—Anaemia—Carmustine—brain cancer	0.000138	0.00176	CcSEcCtD
Carvedilol—Pruritus—Procarbazine—brain cancer	0.000138	0.00176	CcSEcCtD
Carvedilol—KCNH2—midbrain—brain cancer	0.000137	0.00195	CbGeAlD
Carvedilol—Vision blurred—Temozolomide—brain cancer	0.000136	0.00174	CcSEcCtD
Carvedilol—ADRA2C—midbrain—brain cancer	0.000135	0.00192	CbGeAlD
Carvedilol—Dyspnoea—Hydroxyurea—brain cancer	0.000135	0.00172	CcSEcCtD
Carvedilol—Somnolence—Hydroxyurea—brain cancer	0.000134	0.00171	CcSEcCtD
Carvedilol—Ill-defined disorder—Temozolomide—brain cancer	0.000134	0.00171	CcSEcCtD
Carvedilol—Leukopenia—Carmustine—brain cancer	0.000134	0.00171	CcSEcCtD
Carvedilol—KCNH2—spinal cord—brain cancer	0.000134	0.0019	CbGeAlD
Carvedilol—Anaemia—Temozolomide—brain cancer	0.000134	0.0017	CcSEcCtD
Carvedilol—Diarrhoea—Procarbazine—brain cancer	0.000133	0.0017	CcSEcCtD
Carvedilol—Dyspepsia—Hydroxyurea—brain cancer	0.000133	0.0017	CcSEcCtD
Carvedilol—Hypoaesthesia—Etoposide—brain cancer	0.000132	0.00169	CcSEcCtD
Carvedilol—Angioedema—Temozolomide—brain cancer	0.000132	0.00169	CcSEcCtD
Carvedilol—ADRA2C—spinal cord—brain cancer	0.000132	0.00187	CbGeAlD
Carvedilol—Decreased appetite—Hydroxyurea—brain cancer	0.000131	0.00167	CcSEcCtD
Carvedilol—Urinary tract disorder—Etoposide—brain cancer	0.000131	0.00167	CcSEcCtD
Carvedilol—CYP2D6—brainstem—brain cancer	0.000131	0.00186	CbGeAlD
Carvedilol—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00013	0.00166	CcSEcCtD
Carvedilol—Malaise—Temozolomide—brain cancer	0.00013	0.00166	CcSEcCtD
Carvedilol—Urethral disorder—Etoposide—brain cancer	0.00013	0.00166	CcSEcCtD
Carvedilol—Fatigue—Hydroxyurea—brain cancer	0.00013	0.00166	CcSEcCtD
Carvedilol—Vertigo—Temozolomide—brain cancer	0.00013	0.00166	CcSEcCtD
Carvedilol—Convulsion—Carmustine—brain cancer	0.00013	0.00165	CcSEcCtD
Carvedilol—Leukopenia—Temozolomide—brain cancer	0.000129	0.00165	CcSEcCtD
Carvedilol—Hypertension—Carmustine—brain cancer	0.000129	0.00165	CcSEcCtD
Carvedilol—Constipation—Hydroxyurea—brain cancer	0.000129	0.00165	CcSEcCtD
Carvedilol—Pain—Hydroxyurea—brain cancer	0.000129	0.00165	CcSEcCtD
Carvedilol—Dizziness—Procarbazine—brain cancer	0.000129	0.00165	CcSEcCtD
Carvedilol—Palpitations—Temozolomide—brain cancer	0.000128	0.00163	CcSEcCtD
Carvedilol—Chest pain—Carmustine—brain cancer	0.000127	0.00162	CcSEcCtD
Carvedilol—Myalgia—Carmustine—brain cancer	0.000127	0.00162	CcSEcCtD
Carvedilol—Cough—Temozolomide—brain cancer	0.000126	0.00161	CcSEcCtD
Carvedilol—Erythema multiforme—Etoposide—brain cancer	0.000126	0.0016	CcSEcCtD
Carvedilol—ADRA2A—gonad—brain cancer	0.000125	0.00178	CbGeAlD
Carvedilol—Convulsion—Temozolomide—brain cancer	0.000125	0.0016	CcSEcCtD
Carvedilol—Hypertension—Temozolomide—brain cancer	0.000125	0.00159	CcSEcCtD
Carvedilol—ADRA1A—endocrine gland—brain cancer	0.000125	0.00177	CbGeAlD
Carvedilol—Feeling abnormal—Hydroxyurea—brain cancer	0.000124	0.00159	CcSEcCtD
Carvedilol—Vomiting—Procarbazine—brain cancer	0.000124	0.00158	CcSEcCtD
Carvedilol—Confusional state—Carmustine—brain cancer	0.000123	0.00157	CcSEcCtD
Carvedilol—Myalgia—Temozolomide—brain cancer	0.000123	0.00157	CcSEcCtD
Carvedilol—Arthralgia—Temozolomide—brain cancer	0.000123	0.00157	CcSEcCtD
Carvedilol—ADRA1A—head—brain cancer	0.000123	0.00175	CbGeAlD
Carvedilol—Rash—Procarbazine—brain cancer	0.000123	0.00157	CcSEcCtD
Carvedilol—Dermatitis—Procarbazine—brain cancer	0.000123	0.00157	CcSEcCtD
Carvedilol—ADRA2A—pituitary gland—brain cancer	0.000122	0.00174	CbGeAlD
Carvedilol—Headache—Procarbazine—brain cancer	0.000122	0.00156	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000122	0.00156	CcSEcCtD
Carvedilol—Oedema—Carmustine—brain cancer	0.000122	0.00156	CcSEcCtD
Carvedilol—Discomfort—Temozolomide—brain cancer	0.000122	0.00155	CcSEcCtD
Carvedilol—Infection—Carmustine—brain cancer	0.000121	0.00155	CcSEcCtD
Carvedilol—Angiopathy—Etoposide—brain cancer	0.000121	0.00154	CcSEcCtD
Carvedilol—KCNH2—endocrine gland—brain cancer	0.00012	0.00171	CbGeAlD
Carvedilol—Dry mouth—Temozolomide—brain cancer	0.00012	0.00154	CcSEcCtD
Carvedilol—Immune system disorder—Etoposide—brain cancer	0.00012	0.00153	CcSEcCtD
Carvedilol—Mediastinal disorder—Etoposide—brain cancer	0.00012	0.00153	CcSEcCtD
Carvedilol—Thrombocytopenia—Carmustine—brain cancer	0.00012	0.00152	CcSEcCtD
Carvedilol—Body temperature increased—Hydroxyurea—brain cancer	0.000119	0.00152	CcSEcCtD
Carvedilol—Tachycardia—Carmustine—brain cancer	0.000119	0.00152	CcSEcCtD
Carvedilol—Confusional state—Temozolomide—brain cancer	0.000119	0.00152	CcSEcCtD
Carvedilol—KCNH2—head—brain cancer	0.000119	0.00169	CbGeAlD
Carvedilol—ADRA2A—medulla oblongata—brain cancer	0.000118	0.00168	CbGeAlD
Carvedilol—Anaphylactic shock—Temozolomide—brain cancer	0.000118	0.00151	CcSEcCtD
Carvedilol—Oedema—Temozolomide—brain cancer	0.000118	0.00151	CcSEcCtD
Carvedilol—Alopecia—Etoposide—brain cancer	0.000117	0.0015	CcSEcCtD
Carvedilol—ADRA2C—head—brain cancer	0.000117	0.00167	CbGeAlD
Carvedilol—Infection—Temozolomide—brain cancer	0.000117	0.0015	CcSEcCtD
Carvedilol—CYP2D6—telencephalon—brain cancer	0.000116	0.00165	CbGeAlD
Carvedilol—Anorexia—Carmustine—brain cancer	0.000116	0.00148	CcSEcCtD
Carvedilol—Nausea—Procarbazine—brain cancer	0.000116	0.00148	CcSEcCtD
Carvedilol—Thrombocytopenia—Temozolomide—brain cancer	0.000115	0.00147	CcSEcCtD
Carvedilol—CYP2E1—medulla oblongata—brain cancer	0.000115	0.00164	CbGeAlD
Carvedilol—PTGS1—pituitary gland—brain cancer	0.000115	0.00164	CbGeAlD
Carvedilol—Skin disorder—Temozolomide—brain cancer	0.000115	0.00146	CcSEcCtD
Carvedilol—Hypotension—Carmustine—brain cancer	0.000114	0.00146	CcSEcCtD
Carvedilol—Hyperhidrosis—Temozolomide—brain cancer	0.000114	0.00145	CcSEcCtD
Carvedilol—ADRB1—brain—brain cancer	0.000113	0.0016	CbGeAlD
Carvedilol—Anorexia—Temozolomide—brain cancer	0.000112	0.00143	CcSEcCtD
Carvedilol—ADRA1A—central nervous system—brain cancer	0.000112	0.0016	CbGeAlD
Carvedilol—Back pain—Etoposide—brain cancer	0.000112	0.00143	CcSEcCtD
Carvedilol—Hypersensitivity—Hydroxyurea—brain cancer	0.000111	0.00142	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Carmustine—brain cancer	0.000111	0.00142	CcSEcCtD
Carvedilol—Muscle spasms—Etoposide—brain cancer	0.000111	0.00142	CcSEcCtD
Carvedilol—Insomnia—Carmustine—brain cancer	0.00011	0.00141	CcSEcCtD
Carvedilol—ADRA1A—cerebellum—brain cancer	0.00011	0.00156	CbGeAlD
Carvedilol—Paraesthesia—Carmustine—brain cancer	0.00011	0.0014	CcSEcCtD
Carvedilol—Dyspnoea—Carmustine—brain cancer	0.000109	0.00139	CcSEcCtD
Carvedilol—Somnolence—Carmustine—brain cancer	0.000109	0.00138	CcSEcCtD
Carvedilol—KCNH2—central nervous system—brain cancer	0.000108	0.00154	CbGeAlD
Carvedilol—Asthenia—Hydroxyurea—brain cancer	0.000108	0.00138	CcSEcCtD
Carvedilol—ADRA2A—midbrain—brain cancer	0.000108	0.00153	CbGeAlD
Carvedilol—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000107	0.00137	CcSEcCtD
Carvedilol—Ill-defined disorder—Etoposide—brain cancer	0.000107	0.00137	CcSEcCtD
Carvedilol—ADRA2C—central nervous system—brain cancer	0.000107	0.00152	CbGeAlD
Carvedilol—Anaemia—Etoposide—brain cancer	0.000107	0.00136	CcSEcCtD
Carvedilol—Insomnia—Temozolomide—brain cancer	0.000107	0.00136	CcSEcCtD
Carvedilol—Decreased appetite—Carmustine—brain cancer	0.000106	0.00135	CcSEcCtD
Carvedilol—KCNH2—cerebellum—brain cancer	0.000106	0.00151	CbGeAlD
Carvedilol—Paraesthesia—Temozolomide—brain cancer	0.000106	0.00135	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Carmustine—brain cancer	0.000105	0.00134	CcSEcCtD
Carvedilol—ADRA2A—spinal cord—brain cancer	0.000105	0.0015	CbGeAlD
Carvedilol—Dyspnoea—Temozolomide—brain cancer	0.000105	0.00134	CcSEcCtD
Carvedilol—Somnolence—Temozolomide—brain cancer	0.000105	0.00134	CcSEcCtD
Carvedilol—ADRA2C—cerebellum—brain cancer	0.000105	0.00149	CbGeAlD
Carvedilol—Pain—Carmustine—brain cancer	0.000104	0.00133	CcSEcCtD
Carvedilol—Constipation—Carmustine—brain cancer	0.000104	0.00133	CcSEcCtD
Carvedilol—Malaise—Etoposide—brain cancer	0.000104	0.00133	CcSEcCtD
Carvedilol—Vertigo—Etoposide—brain cancer	0.000104	0.00133	CcSEcCtD
Carvedilol—Dyspepsia—Temozolomide—brain cancer	0.000104	0.00132	CcSEcCtD
Carvedilol—Leukopenia—Etoposide—brain cancer	0.000104	0.00132	CcSEcCtD
Carvedilol—Diarrhoea—Hydroxyurea—brain cancer	0.000103	0.00132	CcSEcCtD
Carvedilol—CYP1A2—endocrine gland—brain cancer	0.000103	0.00146	CbGeAlD
Carvedilol—CYP2E1—spinal cord—brain cancer	0.000103	0.00146	CbGeAlD
Carvedilol—Decreased appetite—Temozolomide—brain cancer	0.000103	0.00131	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Temozolomide—brain cancer	0.000102	0.0013	CcSEcCtD
Carvedilol—Fatigue—Temozolomide—brain cancer	0.000102	0.0013	CcSEcCtD
Carvedilol—CYP1A1—endocrine gland—brain cancer	0.000102	0.00144	CbGeAlD
Carvedilol—Loss of consciousness—Etoposide—brain cancer	0.000102	0.0013	CcSEcCtD
Carvedilol—Cough—Etoposide—brain cancer	0.000101	0.00129	CcSEcCtD
Carvedilol—Pain—Temozolomide—brain cancer	0.000101	0.00129	CcSEcCtD
Carvedilol—Constipation—Temozolomide—brain cancer	0.000101	0.00129	CcSEcCtD
Carvedilol—Feeling abnormal—Carmustine—brain cancer	0.000101	0.00128	CcSEcCtD
Carvedilol—CYP1A1—head—brain cancer	0.0001	0.00143	CbGeAlD
Carvedilol—Convulsion—Etoposide—brain cancer	0.0001	0.00128	CcSEcCtD
Carvedilol—Hypertension—Etoposide—brain cancer	9.99e-05	0.00127	CcSEcCtD
Carvedilol—Dizziness—Hydroxyurea—brain cancer	9.98e-05	0.00127	CcSEcCtD
Carvedilol—Gastrointestinal pain—Carmustine—brain cancer	9.98e-05	0.00127	CcSEcCtD
Carvedilol—PTGS1—spinal cord—brain cancer	9.92e-05	0.00141	CbGeAlD
Carvedilol—Chest pain—Etoposide—brain cancer	9.85e-05	0.00126	CcSEcCtD
Carvedilol—CYP2C9—endocrine gland—brain cancer	9.78e-05	0.00139	CbGeAlD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	9.78e-05	0.00125	CcSEcCtD
Carvedilol—Discomfort—Etoposide—brain cancer	9.73e-05	0.00124	CcSEcCtD
Carvedilol—Feeling abnormal—Temozolomide—brain cancer	9.72e-05	0.00124	CcSEcCtD
Carvedilol—Body temperature increased—Carmustine—brain cancer	9.65e-05	0.00123	CcSEcCtD
Carvedilol—Abdominal pain—Carmustine—brain cancer	9.65e-05	0.00123	CcSEcCtD
Carvedilol—Gastrointestinal pain—Temozolomide—brain cancer	9.65e-05	0.00123	CcSEcCtD
Carvedilol—Vomiting—Hydroxyurea—brain cancer	9.6e-05	0.00122	CcSEcCtD
Carvedilol—Rash—Hydroxyurea—brain cancer	9.52e-05	0.00121	CcSEcCtD
Carvedilol—Confusional state—Etoposide—brain cancer	9.52e-05	0.00121	CcSEcCtD
Carvedilol—Dermatitis—Hydroxyurea—brain cancer	9.51e-05	0.00121	CcSEcCtD
Carvedilol—ADRA2A—endocrine gland—brain cancer	9.48e-05	0.00135	CbGeAlD
Carvedilol—Headache—Hydroxyurea—brain cancer	9.46e-05	0.00121	CcSEcCtD
Carvedilol—Anaphylactic shock—Etoposide—brain cancer	9.44e-05	0.0012	CcSEcCtD
Carvedilol—Infection—Etoposide—brain cancer	9.38e-05	0.0012	CcSEcCtD
Carvedilol—Urticaria—Temozolomide—brain cancer	9.37e-05	0.0012	CcSEcCtD
Carvedilol—ADRA2A—head—brain cancer	9.36e-05	0.00133	CbGeAlD
Carvedilol—Abdominal pain—Temozolomide—brain cancer	9.32e-05	0.00119	CcSEcCtD
Carvedilol—Body temperature increased—Temozolomide—brain cancer	9.32e-05	0.00119	CcSEcCtD
Carvedilol—CYP2E1—endocrine gland—brain cancer	9.27e-05	0.00132	CbGeAlD
Carvedilol—Thrombocytopenia—Etoposide—brain cancer	9.24e-05	0.00118	CcSEcCtD
Carvedilol—Tachycardia—Etoposide—brain cancer	9.21e-05	0.00118	CcSEcCtD
Carvedilol—Skin disorder—Etoposide—brain cancer	9.17e-05	0.00117	CcSEcCtD
Carvedilol—CYP1A1—central nervous system—brain cancer	9.16e-05	0.0013	CbGeAlD
Carvedilol—CYP2E1—head—brain cancer	9.15e-05	0.0013	CbGeAlD
Carvedilol—Hyperhidrosis—Etoposide—brain cancer	9.13e-05	0.00116	CcSEcCtD
Carvedilol—Anorexia—Etoposide—brain cancer	9e-05	0.00115	CcSEcCtD
Carvedilol—Hypersensitivity—Carmustine—brain cancer	8.99e-05	0.00115	CcSEcCtD
Carvedilol—Nausea—Hydroxyurea—brain cancer	8.97e-05	0.00114	CcSEcCtD
Carvedilol—PTGS1—endocrine gland—brain cancer	8.93e-05	0.00127	CbGeAlD
Carvedilol—ADRA1A—brain—brain cancer	8.92e-05	0.00127	CbGeAlD
Carvedilol—Hypotension—Etoposide—brain cancer	8.82e-05	0.00113	CcSEcCtD
Carvedilol—PTGS1—head—brain cancer	8.82e-05	0.00125	CbGeAlD
Carvedilol—Asthenia—Carmustine—brain cancer	8.76e-05	0.00112	CcSEcCtD
Carvedilol—Hypersensitivity—Temozolomide—brain cancer	8.69e-05	0.00111	CcSEcCtD
Carvedilol—KCNH2—brain—brain cancer	8.61e-05	0.00122	CbGeAlD
Carvedilol—ADRA2A—central nervous system—brain cancer	8.54e-05	0.00121	CbGeAlD
Carvedilol—ADRA2C—brain—brain cancer	8.5e-05	0.00121	CbGeAlD
Carvedilol—Paraesthesia—Etoposide—brain cancer	8.48e-05	0.00108	CcSEcCtD
Carvedilol—Asthenia—Temozolomide—brain cancer	8.46e-05	0.00108	CcSEcCtD
Carvedilol—Dyspnoea—Etoposide—brain cancer	8.42e-05	0.00107	CcSEcCtD
Carvedilol—Somnolence—Etoposide—brain cancer	8.39e-05	0.00107	CcSEcCtD
Carvedilol—ABCB1—telencephalon—brain cancer	8.37e-05	0.00119	CbGeAlD
Carvedilol—CYP2E1—central nervous system—brain cancer	8.35e-05	0.00119	CbGeAlD
Carvedilol—Diarrhoea—Carmustine—brain cancer	8.35e-05	0.00107	CcSEcCtD
Carvedilol—ADRA2A—cerebellum—brain cancer	8.35e-05	0.00119	CbGeAlD
Carvedilol—Pruritus—Temozolomide—brain cancer	8.35e-05	0.00106	CcSEcCtD
Carvedilol—Decreased appetite—Etoposide—brain cancer	8.21e-05	0.00105	CcSEcCtD
Carvedilol—CYP2E1—cerebellum—brain cancer	8.17e-05	0.00116	CbGeAlD
Carvedilol—Gastrointestinal disorder—Etoposide—brain cancer	8.15e-05	0.00104	CcSEcCtD
Carvedilol—Fatigue—Etoposide—brain cancer	8.14e-05	0.00104	CcSEcCtD
Carvedilol—Dizziness—Carmustine—brain cancer	8.07e-05	0.00103	CcSEcCtD
Carvedilol—Pain—Etoposide—brain cancer	8.07e-05	0.00103	CcSEcCtD
Carvedilol—Constipation—Etoposide—brain cancer	8.07e-05	0.00103	CcSEcCtD
Carvedilol—Diarrhoea—Temozolomide—brain cancer	8.07e-05	0.00103	CcSEcCtD
Carvedilol—PTGS1—central nervous system—brain cancer	8.05e-05	0.00114	CbGeAlD
Carvedilol—Dizziness—Temozolomide—brain cancer	7.8e-05	0.000995	CcSEcCtD
Carvedilol—Feeling abnormal—Etoposide—brain cancer	7.78e-05	0.000992	CcSEcCtD
Carvedilol—Vomiting—Carmustine—brain cancer	7.76e-05	0.00099	CcSEcCtD
Carvedilol—Gastrointestinal pain—Etoposide—brain cancer	7.72e-05	0.000985	CcSEcCtD
Carvedilol—Rash—Carmustine—brain cancer	7.7e-05	0.000982	CcSEcCtD
Carvedilol—Dermatitis—Carmustine—brain cancer	7.69e-05	0.000981	CcSEcCtD
Carvedilol—Headache—Carmustine—brain cancer	7.65e-05	0.000976	CcSEcCtD
Carvedilol—Vomiting—Temozolomide—brain cancer	7.5e-05	0.000957	CcSEcCtD
Carvedilol—Urticaria—Etoposide—brain cancer	7.5e-05	0.000957	CcSEcCtD
Carvedilol—Abdominal pain—Etoposide—brain cancer	7.46e-05	0.000952	CcSEcCtD
Carvedilol—Body temperature increased—Etoposide—brain cancer	7.46e-05	0.000952	CcSEcCtD
Carvedilol—CYP3A4—endocrine gland—brain cancer	7.46e-05	0.00106	CbGeAlD
Carvedilol—Rash—Temozolomide—brain cancer	7.44e-05	0.000949	CcSEcCtD
Carvedilol—Dermatitis—Temozolomide—brain cancer	7.43e-05	0.000948	CcSEcCtD
Carvedilol—Headache—Temozolomide—brain cancer	7.39e-05	0.000943	CcSEcCtD
Carvedilol—CYP2D6—endocrine gland—brain cancer	7.34e-05	0.00104	CbGeAlD
Carvedilol—CYP1A1—brain—brain cancer	7.27e-05	0.00103	CbGeAlD
Carvedilol—Nausea—Carmustine—brain cancer	7.25e-05	0.000925	CcSEcCtD
Carvedilol—CYP2D6—head—brain cancer	7.25e-05	0.00103	CbGeAlD
Carvedilol—Nausea—Temozolomide—brain cancer	7.01e-05	0.000894	CcSEcCtD
Carvedilol—ABCB1—gonad—brain cancer	6.99e-05	0.000992	CbGeAlD
Carvedilol—Hypersensitivity—Etoposide—brain cancer	6.95e-05	0.000887	CcSEcCtD
Carvedilol—ABCB1—pituitary gland—brain cancer	6.82e-05	0.000968	CbGeAlD
Carvedilol—ADRA2A—brain—brain cancer	6.78e-05	0.000963	CbGeAlD
Carvedilol—Asthenia—Etoposide—brain cancer	6.77e-05	0.000864	CcSEcCtD
Carvedilol—CYP3A4—central nervous system—brain cancer	6.72e-05	0.000955	CbGeAlD
Carvedilol—Pruritus—Etoposide—brain cancer	6.68e-05	0.000852	CcSEcCtD
Carvedilol—CYP2E1—brain—brain cancer	6.63e-05	0.000942	CbGeAlD
Carvedilol—CYP2D6—central nervous system—brain cancer	6.61e-05	0.000939	CbGeAlD
Carvedilol—ABCB1—medulla oblongata—brain cancer	6.58e-05	0.000934	CbGeAlD
Carvedilol—CYP2D6—cerebellum—brain cancer	6.47e-05	0.000918	CbGeAlD
Carvedilol—Diarrhoea—Etoposide—brain cancer	6.46e-05	0.000824	CcSEcCtD
Carvedilol—Propafenone—CYP2C9—brain cancer	6.4e-05	1	CrCbGaD
Carvedilol—PTGS1—brain—brain cancer	6.39e-05	0.000907	CbGeAlD
Carvedilol—Dizziness—Etoposide—brain cancer	6.24e-05	0.000796	CcSEcCtD
Carvedilol—ABCB1—midbrain—brain cancer	6.01e-05	0.000854	CbGeAlD
Carvedilol—Vomiting—Etoposide—brain cancer	6e-05	0.000766	CcSEcCtD
Carvedilol—Rash—Etoposide—brain cancer	5.95e-05	0.000759	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—brain cancer	5.95e-05	0.000759	CcSEcCtD
Carvedilol—Headache—Etoposide—brain cancer	5.91e-05	0.000754	CcSEcCtD
Carvedilol—ABCB1—spinal cord—brain cancer	5.87e-05	0.000833	CbGeAlD
Carvedilol—Nausea—Etoposide—brain cancer	5.61e-05	0.000715	CcSEcCtD
Carvedilol—ABCB1—endocrine gland—brain cancer	5.28e-05	0.00075	CbGeAlD
Carvedilol—CYP2D6—brain—brain cancer	5.25e-05	0.000746	CbGeAlD
Carvedilol—ABCB1—head—brain cancer	5.21e-05	0.00074	CbGeAlD
Carvedilol—ABCB1—central nervous system—brain cancer	4.76e-05	0.000676	CbGeAlD
Carvedilol—ABCB1—cerebellum—brain cancer	4.65e-05	0.000661	CbGeAlD
Carvedilol—ABCB1—brain—brain cancer	3.78e-05	0.000537	CbGeAlD
Carvedilol—ADRB2—GPCR downstream signaling—PIK3CG—brain cancer	6.24e-06	7.04e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOTCH2—brain cancer	6.21e-06	7e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ENO2—brain cancer	6.16e-06	6.95e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	6.16e-06	6.95e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SHH—brain cancer	6.04e-06	6.81e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—brain cancer	6.03e-06	6.8e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—VEGFA—brain cancer	5.98e-06	6.75e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.98e-06	6.75e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VAV1—brain cancer	5.92e-06	6.68e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—PIK3CG—brain cancer	5.91e-06	6.66e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—IDH1—brain cancer	5.87e-06	6.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TRPC6—brain cancer	5.82e-06	6.57e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—PIK3CG—brain cancer	5.81e-06	6.56e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ENO2—brain cancer	5.81e-06	6.55e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PIK3CG—brain cancer	5.79e-06	6.54e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—APC—brain cancer	5.77e-06	6.51e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PIK3CG—brain cancer	5.77e-06	6.51e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PIK3CG—brain cancer	5.76e-06	6.49e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—APC—brain cancer	5.76e-06	6.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PIK3CG—brain cancer	5.74e-06	6.48e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SMO—brain cancer	5.72e-06	6.46e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTCH1—brain cancer	5.72e-06	6.46e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PIK3CG—brain cancer	5.67e-06	6.4e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOTCH2—brain cancer	5.66e-06	6.38e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SHH—brain cancer	5.61e-06	6.33e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOTCH2—brain cancer	5.6e-06	6.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—VEGFA—brain cancer	5.59e-06	6.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOTCH2—brain cancer	5.53e-06	6.24e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—IDH1—brain cancer	5.53e-06	6.24e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—IDH1—brain cancer	5.48e-06	6.19e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—BSG—brain cancer	5.45e-06	6.15e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TRPC6—brain cancer	5.41e-06	6.1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VAV1—brain cancer	5.39e-06	6.08e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PIK3CG—brain cancer	5.36e-06	6.05e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VAV1—brain cancer	5.34e-06	6.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—IL2—brain cancer	5.34e-06	6.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTCH1—brain cancer	5.32e-06	6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMO—brain cancer	5.32e-06	6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CG—brain cancer	5.28e-06	5.96e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VAV1—brain cancer	5.27e-06	5.95e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—brain cancer	5.25e-06	5.93e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOTCH2—brain cancer	5.23e-06	5.91e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.17e-06	5.83e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CG—brain cancer	5.16e-06	5.83e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOTCH2—brain cancer	5.15e-06	5.81e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HES1—brain cancer	5.09e-06	5.74e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VAV1—brain cancer	4.99e-06	5.63e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP2C9—brain cancer	4.95e-06	5.58e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—IL2—brain cancer	4.93e-06	5.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VAV1—brain cancer	4.91e-06	5.54e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PDGFRA—brain cancer	4.85e-06	5.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CG—brain cancer	4.8e-06	5.41e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SPP1—brain cancer	4.7e-06	5.31e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CG—brain cancer	4.69e-06	5.29e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—IDH1—brain cancer	4.69e-06	5.29e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ENO2—brain cancer	4.64e-06	5.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HES1—brain cancer	4.64e-06	5.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HES1—brain cancer	4.59e-06	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOTCH2—brain cancer	4.58e-06	5.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—VEGFA—brain cancer	4.54e-06	5.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HES1—brain cancer	4.54e-06	5.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—brain cancer	4.52e-06	5.1e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—RELA—brain cancer	4.51e-06	5.08e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—RELA—brain cancer	4.5e-06	5.07e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—IL2—brain cancer	4.49e-06	5.07e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—ERBB2—brain cancer	4.48e-06	5.05e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL2—brain cancer	4.48e-06	5.05e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ERBB2—brain cancer	4.47e-06	5.04e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.46e-06	5.04e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—IL2—brain cancer	4.45e-06	5.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PDGFRA—brain cancer	4.41e-06	4.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—IL2—brain cancer	4.39e-06	4.96e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PDGFRA—brain cancer	4.37e-06	4.94e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ENO2—brain cancer	4.37e-06	4.93e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VAV1—brain cancer	4.36e-06	4.92e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CG—brain cancer	4.36e-06	4.92e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ENO2—brain cancer	4.33e-06	4.89e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PDGFRA—brain cancer	4.32e-06	4.87e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HES1—brain cancer	4.29e-06	4.84e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SPP1—brain cancer	4.29e-06	4.84e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IRS2—brain cancer	4.25e-06	4.8e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOTCH2—brain cancer	4.25e-06	4.8e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SPP1—brain cancer	4.25e-06	4.79e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HES1—brain cancer	4.22e-06	4.77e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—brain cancer	4.22e-06	4.76e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—BSG—brain cancer	4.2e-06	4.74e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SPP1—brain cancer	4.19e-06	4.73e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL2—brain cancer	4.16e-06	4.69e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL2—brain cancer	4.09e-06	4.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PDGFRA—brain cancer	4.09e-06	4.61e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL2—brain cancer	4.08e-06	4.6e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL2—brain cancer	4.06e-06	4.58e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VAV1—brain cancer	4.05e-06	4.57e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL2—brain cancer	4.05e-06	4.57e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL2—brain cancer	4.04e-06	4.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PDGFRA—brain cancer	4.02e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL2—brain cancer	3.99e-06	4.5e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SPP1—brain cancer	3.97e-06	4.48e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCND1—brain cancer	3.96e-06	4.46e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCND1—brain cancer	3.95e-06	4.45e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CTNNB1—brain cancer	3.92e-06	4.42e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CTNNB1—brain cancer	3.91e-06	4.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SPP1—brain cancer	3.9e-06	4.4e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IRS2—brain cancer	3.88e-06	4.37e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IRS2—brain cancer	3.84e-06	4.33e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.81e-06	4.3e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IRS2—brain cancer	3.79e-06	4.28e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CG—brain cancer	3.79e-06	4.28e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CG—brain cancer	3.78e-06	4.27e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL2—brain cancer	3.77e-06	4.26e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CG—brain cancer	3.76e-06	4.24e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—APC—brain cancer	3.76e-06	4.24e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HES1—brain cancer	3.75e-06	4.23e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL2—brain cancer	3.71e-06	4.19e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO2—brain cancer	3.7e-06	4.18e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL2—brain cancer	3.63e-06	4.1e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—IDH1—brain cancer	3.62e-06	4.08e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IRS2—brain cancer	3.59e-06	4.05e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PDGFRA—brain cancer	3.57e-06	4.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IRS2—brain cancer	3.53e-06	3.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HES1—brain cancer	3.49e-06	3.93e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SPP1—brain cancer	3.47e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—VEGFA—brain cancer	3.45e-06	3.89e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—brain cancer	3.43e-06	3.87e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—APC—brain cancer	3.42e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CG—brain cancer	3.42e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—brain cancer	3.42e-06	3.86e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—STAT3—brain cancer	3.42e-06	3.85e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—STAT3—brain cancer	3.41e-06	3.85e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CG—brain cancer	3.39e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—APC—brain cancer	3.39e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2—brain cancer	3.38e-06	3.81e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CG—brain cancer	3.35e-06	3.78e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—APC—brain cancer	3.35e-06	3.78e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PDGFRA—brain cancer	3.32e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2—brain cancer	3.3e-06	3.72e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SPP1—brain cancer	3.22e-06	3.64e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MYC—brain cancer	3.17e-06	3.58e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CG—brain cancer	3.17e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—APC—brain cancer	3.17e-06	3.57e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MYC—brain cancer	3.17e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IRS2—brain cancer	3.14e-06	3.54e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—brain cancer	3.12e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CG—brain cancer	3.12e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—APC—brain cancer	3.12e-06	3.52e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—brain cancer	3.1e-06	3.5e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—brain cancer	3.1e-06	3.49e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—brain cancer	3.09e-06	3.49e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CG—brain cancer	3.08e-06	3.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—brain cancer	3.07e-06	3.46e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—brain cancer	3.05e-06	3.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RELA—brain cancer	2.94e-06	3.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—brain cancer	2.92e-06	3.29e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IRS2—brain cancer	2.91e-06	3.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—brain cancer	2.89e-06	3.26e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO2—brain cancer	2.86e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—brain cancer	2.84e-06	3.21e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CG—brain cancer	2.83e-06	3.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CG—brain cancer	2.77e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—APC—brain cancer	2.77e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RELA—brain cancer	2.67e-06	3.02e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CG—brain cancer	2.66e-06	3.01e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—brain cancer	2.66e-06	3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RELA—brain cancer	2.65e-06	2.99e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—brain cancer	2.64e-06	2.98e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—brain cancer	2.63e-06	2.97e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RELA—brain cancer	2.62e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—brain cancer	2.61e-06	2.94e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—brain cancer	2.6e-06	2.93e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—brain cancer	2.6e-06	2.93e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—brain cancer	2.58e-06	2.91e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CG—brain cancer	2.57e-06	2.9e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—APC—brain cancer	2.57e-06	2.9e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CTNNB1—brain cancer	2.55e-06	2.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—brain cancer	2.52e-06	2.85e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RELA—brain cancer	2.48e-06	2.79e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—brain cancer	2.46e-06	2.78e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RELA—brain cancer	2.44e-06	2.75e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—brain cancer	2.42e-06	2.73e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—brain cancer	2.41e-06	2.72e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—brain cancer	2.39e-06	2.69e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—brain cancer	2.36e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—brain cancer	2.35e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—brain cancer	2.34e-06	2.65e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—brain cancer	2.33e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—brain cancer	2.33e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—brain cancer	2.3e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—brain cancer	2.3e-06	2.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—brain cancer	2.27e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—brain cancer	2.25e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—brain cancer	2.23e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—brain cancer	2.22e-06	2.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—brain cancer	2.19e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—brain cancer	2.17e-06	2.45e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RELA—brain cancer	2.16e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—brain cancer	2.15e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—brain cancer	2.15e-06	2.43e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—brain cancer	2.14e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—brain cancer	2.13e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—brain cancer	2.12e-06	2.39e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—brain cancer	2.07e-06	2.33e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—brain cancer	2.05e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—brain cancer	2.03e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—brain cancer	2.03e-06	2.29e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—brain cancer	2.02e-06	2.28e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RELA—brain cancer	2.01e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—brain cancer	2.01e-06	2.27e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—brain cancer	2.01e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—brain cancer	2e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—brain cancer	2e-06	2.25e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—brain cancer	1.99e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—brain cancer	1.98e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—brain cancer	1.95e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—brain cancer	1.9e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—brain cancer	1.89e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—brain cancer	1.88e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—brain cancer	1.88e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—brain cancer	1.88e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—brain cancer	1.87e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—brain cancer	1.86e-06	2.1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—brain cancer	1.85e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—brain cancer	1.84e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—brain cancer	1.84e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—brain cancer	1.83e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—brain cancer	1.81e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—brain cancer	1.8e-06	2.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—brain cancer	1.77e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—brain cancer	1.75e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—brain cancer	1.74e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—brain cancer	1.72e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—brain cancer	1.71e-06	1.92e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—brain cancer	1.7e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—brain cancer	1.7e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—brain cancer	1.68e-06	1.89e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—brain cancer	1.66e-06	1.87e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—brain cancer	1.64e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—brain cancer	1.55e-06	1.75e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—brain cancer	1.54e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—brain cancer	1.53e-06	1.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—brain cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—brain cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—brain cancer	1.51e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—brain cancer	1.49e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—brain cancer	1.43e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—brain cancer	1.42e-06	1.6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—brain cancer	1.41e-06	1.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—brain cancer	1.39e-06	1.56e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—brain cancer	1.31e-06	1.48e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—brain cancer	1.25e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—brain cancer	1.16e-06	1.31e-05	CbGpPWpGaD
